Malawi.png' alt='Complementary Feeding Programs Philippines' title='Complementary Feeding Programs Philippines' />AIPPI 2. AIPPI World Congress Milan. Panel Session Brexit Implications for IPSunday, September 1. AIPPI is pleased to announce that the professional development programme of the Congress will now commence  with a briefing on the implications for IP rights  in the UK and the EU. Our panellists will debate topics including possible changes to substantive IP laws where they have been harmonized at EU levelthe role of national case law once the Court of Justice for the European Union is no longer  competent for prejudicial interpretation regarding the UK lawthe role of the EPO in maintaining  harmonization of the interpretation of the substantive rules of patent lawenforcement strategies in cases with cross border issues,as well as the implications for the EU IPR Enforcement Directive. Brussels Regulation Rome II and service issuesthe European Digital Single Marketthe Biotech Directive. Customs seizuresexhaustions of rightslicensing, settlements and competition issuestransitional provisions. The panel will also explore the treaty implications relevant to various proposals for managing IP in the context of Brexit as well as the different impacts on IP as a function of the different models the UK could adopt outside the EU, such as the  Norway model, bilateral agreements or a WTO only model. Moderator. Speakers. Introduction and Acknowledgements This is a the first edition of a briefing guide for the successful implementation of urban and periurban agriculture UPA in. Women and Heart Disease Across the Lifespan 40021 National Health Programs India. INTRODUCTION 40031 Vector Borne Diseases Control Program. Guiuan-Basey-144-for-web.jpg' alt='Complementary Feeding Programs Philippines' title='Complementary Feeding Programs Philippines' />Pharma Session 1 Ingeneious but not patentable Patentable subject matter. Monday, September 1. The patentability of inventions relating to genes, stem cells or other biological material, dosage regime and diagnostic testing, amongst other topics, has always been of primary importance for the life sciences industry from fundamental research institutes to pharmaceutical companies. Recent years have seen an apparent reversal in the approach to patentability. The US Supreme Court seems to have abandoned its anything under the sun doctrine with its very restrictive decisions in the Prometheus and Myriad cases Australia seems to be following suit. Paradoxically, in light of how difficult it was to adopt, Europe seems to have been insulated from this trend by the operation of the Directive on the legal protection of biotechnological inventions, although the Directive leaves many issues open. The evolving position in Asia is uncertain and far from uniform. GOLDEN RICE NOW Showing the dark side of the anti GM campaigners. Save Game Gta Sa'>Save Game Gta Sa. Teoria De Las Relaciones Humanas Chiavenato Pdf on this page. This initiative, led by Dr Patrick Moore, cofounder and 15 years leader of Greenpeace and longtime. The 2016 AIPPI World Congress took place in Milan, home of fashion, industry and design. Milan offered a pleasant environment to learn and discuss hot IP topics Early childhood development ECD has become a priority for research, policy and programming, at national and global level, with increasing recognition of the. CONTENTS 1. Introduction 1 2. World Tourism Organisation Indicators 2 3. UN Commission on Sustainable Development Indicators of Sustainable Development. Mothers-and-Children-775x517.jpg' alt='Complementary Feeding Programs Philippines' title='Complementary Feeding Programs Philippines' />This panel session will review the current state of the law and policy trends in relation to patentable subject matter in key jurisdictions. In particular, it will focus on the consequences for industry of these recent changes. The panel will also discuss the question of what the appropriate boundaries for patentable subject matter should be. Moderator. Speakers. Pharma Session 2 Biosimilars similar but different Monday, September 1. Medicines made via biotechnology involving living organisms are more complex than conventional medicines also referred to as small molecule drugs. Being made of chemical substances, the structure of a small molecule drug can be identified, and an identical compound can be synthesized. As the copy can be considered bioequivalent, regulatory authorities can be confident this generic version should produce the same result in patients. Biologic medicines are more difficult to identify and characterize. While a biologic has no generic equivalent, from a regulatory perspective, biosimilars are expected to have no clinically meaningful difference for the patient in terms of safety and efficacy, and should be highly comparable to the reference biologic medicine. Some regulatory authorities further distinguish biosimilar medicines by whether they are also interchangeable with the reference product. Interchangeable medicines are also expected to produce no different results in any patient, even if alternated with the reference product. Many innovator biopharma companies have developed or are developing biologics. Competition from biosimilars and interchangeable products is growing. Because they may differ structurally from the reference product, they may not fall within any relevant patent claims covering the reference product. Around the world, regulatory agencies have taken varied approaches to approval of biosimilar and interchangeable products. This may have implications for substitutability and flow on pricing decisions. There are also implications for exclusivity, whether by patent protection or other means. This session will involve examination of these issues by a variety of both regulatory and patent specialists, including in house counsel. Moderator. Speakers. Pharma Session 3 Skinny Labels Wide Impact. Monday, September 1. The development of new drugs is highly expensive, with an accompanying high risk of failure. Drug development based on the success of a known active ingredient a second medical use reduces the risk that the active ingredient is not suitable for human application. Such new uses often provide critical solutions to unmet medical needs. However, the ability to obtain and enforce patent protection for second medical uses varies between jurisdictions. The legal uncertainty arising from variation as to the form and availability of claims to second medical uses is particularly acute when patent protection for the original use has expired, but there is a patent in force covering the new use. Generic drugs may be approved for the original use, but with a label which omits any mention of the second use a skinny label, or a label which expressly disclaims the second use. Notwithstanding the patent position, medical practitioners may prescribe, pharmacies may dispense, and patients may use the generic drug not only for the original use. This raises issues for establishing infringement, including whether for example the supplier of the generic drug can be held to have induced the infringement the second medical use patent or who may be liable at all, if the actual infringer is the patient. German and British courts have recently reached diverging positions as to the scope of protection of second medical use patents when it comes to so called skinny labeling or off label use. US courts are also grappling with issues of contributory infringement. The question is therefore how to enforce patents on second medical uses in these circumstances Panelists from the US, Europe and Asia will discuss what claim formats are available, the protection they can provide and the best approaches to protect these important inventions. Moderator. Speakers. Pharma Session 4 Antitrust and Pharma Seeking a Balance. Monday, September 1. While national patent and competition also referred to as anti trust laws can rightly be viewed as two complementary policy regimes for governments to use in the promotion of robust and efficient economies, there has always been a natural tension between the two given that one grants monopoly rights while the other typically is directed to promoting freedom of competition and the avoidance or limitation on monopoly power in the marketplace. For example, while patent protection has for many years been one of the key elements to promoting investment in R D in the pharmaceutical industry, there is an increasing focus by governments, NGOs and others on ensuring that the benefits of any such patent rights be balanced with the public policy goals of providing access to affordable healthcare to individuals and controlling healthcare costs incurred by governments and health care providers.